Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (679)	5/3/1998 12:28:00 PM
From: InvestorLady	Read Replies (2) \| Respond to of 1491

David David David, what toe have I stepped on to elicit such insults? Still wondering how the stage II prior to the Blind study went. You don't know me, so let me give you a brief introduction. I have been an in-depth researcher in the past going beyond the normal paper trail research, have visited management of many companies, checked out product acceptance, etc., etc. The lessons learned have taught me that in early-stage growth stocks things RARELY go as planned. There are disappointments and there are victories. But it is the rare totally rosey picture one finds, as you have painted. I now pay more attention to how a stock is valued by the market and why (as best as can be determined), rather than just my opinion. It is a tough task to do if close to a company, especially if there is strong raport with management. There is the company and then there is the stock. The website response to investor demands is very encouraging for getting information out. PARS is priced under $3 because there are risks involved in the stock (and because of the dilution with 36 million plus shares outstanding). To only look at the exhuberrant side IS A MISTAKE. Price to sales ratio, while useless for an R&D situation, will be a factor coming up. If you could not see the value in my postings, perhaps you need to look again. Admittedly, I have more to learn about this company. Like I said, I am a shareholder as a very dear friend of mine is heavily invested in this stock and she is a very savvy lady. I am friend, not foe. Looking at risk management here. Lady